Hologic reported after the close of the market Thursday that its non-COVID fiscal fourth quarter organic revenues grew 17 percent compared to one year earlier on a constant currency basis with double-digit organic growth across all its divisions.

As a global company with a broad range of businesses, operations in over 160 countries and 115,000 people around the world, diversity is inherent to our business and organization.

Not long after acquiring Resolution Bioscience in a deal worth more than half a billion dollars, Agilent Technologies has resolved to shutter the business, which was developing liquid biopsy tests that were powered by next-generation sequencing technology and meant to be used as companion diagnostics for cancer patients.

Mirxes Holding Company Limited, a Singapore-headquartered RNA technology company that is making diagnostic solutions for the early detection of diseases accessible on a global scale, announced today the successful completion of its Series D funding round, securing a total of US$50 million.

EDP Biotech and New Day Diagnostics announced on Wednesday that they will combine their assets to form a new company.

At 9:30 a.m. on June 30, Adicon was officially listed on the Hong Kong Stock Exchange. Adicon Holdings (09860.HK) is offering 33,192,500 shares globally, of which 3,320,000 shares are offered in Hong Kong, China and 29,872,500 shares are offered internationally, with a 15% over-allotment option.

Bio-Techne announced on Thursday that it is acquiring Swiss spatial biology firm Lunaphore for an undisclosed amount.

The National Institutes of Health (NIH) has awarded a $4.6 million contract to Sorrento Therapeutics to develop an in vitro diagnostic testing platform for biodefense, antimicrobial-resistant infections, and emerging infectious diseases, the firm said Tuesday.

Looking at the overall environment, the receding of the COVID-19 testing dividend, the slowdown of conventional business growth, and the pressure from the collection policy have all brought the IVD industry into an adjustment period.

LumiraDx on Tuesday reported an 82 percent year-over-year decrease in first quarter revenues due to falling demand for COVID-19 testing.